临床儿科杂志 ›› 2015, Vol. 33 ›› Issue (2): 144-.doi: 10.3969 j.issn.1000-3606.2015.02.011

• 综合报道 • 上一篇    下一篇

miR-200a 在儿童急性B 淋巴细胞白血病中表达及意义

高顺利,王立忠,刘海英,刘丹莉   

  1. 南华大学附属第一医院儿科( 湖南衡阳 421001)
  • 收稿日期:2015-02-15 出版日期:2015-02-15 发布日期:2015-02-15
  • 通讯作者: 高顺利 E-mail:gaosl123@163.com
  • 基金资助:
    湖南省教育厅课题资助项目(No.13C802)

Expression and clinical significance of miR-200a in childhood B-cell acute lymphoblastic leukemia

GAO Shunli,WANG Lizhong,LIU Haiying,LIU Danli   

  1. Department of Pediatrics,The First Affiliated Hospital of Nanhua University,Hengyang 421001,Hunan,China
  • Received:2015-02-15 Online:2015-02-15 Published:2015-02-15

摘要: 目的 探讨miR-200a在儿童急性B淋巴细胞白血病中的表达及临床意义。方法 收集B细胞ALL患儿45例,以非血液病患儿18例为对照组,采集骨髓标本,qRT-PCR检测各组miR-200a的表达,并分析B细胞ALL患儿中miR-200a的表达与临床指标间的相关性。结果 miR-200a在B淋巴细胞ALL患儿组中的表达为(3.9±1.4)×10-4,低于对照组(25.7±10.3)×10-4,差异有统计学意义(P<0.05)。在≥10岁B淋巴细胞ALL患儿中miR-200a的表达低于<10岁患儿,差异有统计学意义(P<0.05)。不同治疗阶段和危险度分组miR-200a表达的差异有统计学意义(P<0.05);以治疗第12周以及低危组的表达较高。结论 miR-200a低表达与儿童B细胞ALL的发生发展以及预后密切相关,可作为儿童B细胞ALL预后判断的潜在指标和治疗靶点。

Abstract:  Objective To explore the expression and clinical significance of microRNA-200a in childhood B-cell acute lymphoblastic leukemia (ALL). Methods Bone marrow samples were collected from 45 children with B-cell ALL and 18 children without hematology disease as control. Total RNA was acquired from bone marrow. qRT-PCR was performed to detect the expression level of miR-200a. Results The relative expression level of miR-200a in B-cell ALL group was significantly lower than that in control group (p<0.05); the expression of miR-200a in children over 10 years old was significantly lower than those in children under 10 years old (p<0.05); the expression of miR-200a in newly diagnosed samples was lower than those in those samples taken on Day 33 and at Week 12, respectively (p<0.05, p<0.01). In addition, the expression of miR-200a in low-risk group was higher than those in mid-risk and high-risk group, respectively (p<0.05). Conclusions Low level of miR-200a had a close correlation with the development and prognosis of childhood B cell ALL, which could be used as a potential target of therapy and a biomarker of childhood B cell ALL in the future.